Brazil’s Health Ministry will make women’s health a priority for the next government mandate, with plans announced Wednesday to expand early cancer diagnosis, reorganize oncology care, and develop new actions focused on menopause.
Specialized Health Care Secretary Mozart Sales presented the measures at an event hosted by Esfera Brasil on this Wednesday, 18, in a conversation with Futuro da Saúde. The package spans more screening exams, new equipment purchases, changes to procedure financing, and new care models aimed at cutting delays between diagnosis and treatment.
The oncology targets are three cancers that together account for roughly 48% of new cancer diagnoses in Brazilian women. According to the latest estimate from the National Cancer Institute (Inca), Brazil expects about 78,600 new breast cancer cases, 27,500 colorectal cases, and 19,300 cervical cancer cases per year among women between 2026 and 2028.
Menopause care is another focus. Sales said the topic sits within President Lula’s government plan and that proposals will be developed this year for implementation from 2027.
“It is a commitment of ours and we will improve the care offer in this field. It is completely on our radar. We are committed to planning now, in this final stretch of government, and leaving the measures ready for the new Health Ministry,” he told Futuro da Saúde.
In Plain English: The Clinical Takeaway
- Brazil plans to buy roughly 400 mammography machines for regions with care gaps, on top of the about 3,300 already in the country.
- Cervical cancer screening will expand using molecular tests, with a goal of reaching 70% of women in the screening age range.
- Colorectal screening will start with a stool test, reserving colonoscopy for people whose results come back positive.
Why Breast Cancer Diagnosis Drives the Equipment Push
Breast cancer is one of the priorities in the plan. Sales said the central strategy is to expand screening capacity and reduce diagnoses made at advanced stages. The ministry wants to acquire approximately 400 mammographs destined for regions with care gaps.
A problem the ministry itself flagged: it currently faces difficulties to evaluate the capacity and conditions of the available equipment. Brazil counts around 3,300 mammographs, but a national survey of mammography services is being prepared to identify machine characteristics and qualify network planning, Futuro da Saúde reported.
Payment rules are also changing. “We have also established a new price for mammography on the Agora Tem Especialistas table for exchanging financial credits and parliamentary amendments, and we want to advance with that value in 2027,” Sales said.
Beyond imaging, the ministry wants wider access to technologies for investigating suspicious lesions — microcalcifications and tumors that present difficulties for material collection — including mammotomy and image-guided biopsy, with equipment to analyze samples to favor the diagnosis of tumors in initial stages.
Replacing the Pap Smear, and Restricting Colonoscopy to Those Who Need It
For cervical cancer, the priorities involve expanding HPV vaccination and the national expansion of molecular screening. The expectation, per the secretary, is to reach all 27 federative units by the end of 2026 and progressively widen population coverage through 2027, prioritizing women who have gone longest without preventive exams.
“The Pap smear coverage level in Brazil is insufficient; with the molecular test we can expand that. This initiative is being built with the states and municipalities. We need to give new meaning to the cervical cancer care line. It was somewhat disorganized, with insufficient equipment and no adequate structure for biopsy or pathology laboratories,” Sales said.
Colorectal cancer screening will follow a strategy based on the fecal immunochemical test (FIT), which identifies human blood in stool. The proposal is to use the test as the first investigation step and direct patients with positive results to colonoscopy, rather than resorting to the invasive procedure as an initial exam for the entire population.
The ministry intends to acquire and distribute an initial 400,000 tests by the end of 2026 or early 2027, then expand progressively taking reference from international organized screening experiences.
The Pathology Bottleneck a New Payment Policy Tries to Fix
Diagnosis speed depends on pathologists, and that is where the text notes ongoing challenges. The A.C.Camargo Cancer Center launched its Super Center for Cancer Diagnosis in 2025 under the Proadi-SUS program to accelerate diagnosis, initially able to issue up to 1,000 reports per day starting in September 2025. After one year of the initiative, the project still presents difficulties to meet the anticipated capacity, Futuro da Saúde reported.
To strengthen the network, seven of the eight regional pathology hubs are expected to be operating by December this year. A new national pathology remuneration policy is also in preparation, designed to separate the stages of the production chain to allow the remuneration of remote reports and more complex procedures.
The funding shift is substantial: “We used to spend 150 million reais on pathology in Brazil. With the new policy, we will spend around 450 million reais. It is something very necessary and we are convinced that the challenge of fighting cancer goes through this,” Sales said.
Payment tables for procedures will also be updated to widen access to molecular and genetic tests, as well as the acquisition of devices and values paid for brachytherapy and radiotherapy procedures.
| Cancer type (women) | New cases per year, 2026–2028 (Inca estimate) | Key 2027 strategy |
|---|---|---|
| Breast | ~78,600 | ~400 new mammographs; new mammography price in 2027 |
| Colorectal | ~27,500 | FIT stool test first; 400,000 initial tests |
| Cervical | ~19,300 | Molecular testing in all 27 states; 70% coverage goal |
What Remains Unsettled
Several pieces of the plan involve preparations and proposals. The menopause initiatives involve developing proposals this year to be implemented from 2027. The mammography equipment census is being prepared to identify characteristics and qualify planning. The FIT-based colorectal screening strategy is to be expanded progressively taking reference from international experiences. And the pathology remuneration policy is in preparation.
Sales said that it will be necessary to establish more aggressive and radical policies to define supply parameters and ensure compliance with minimum indicator targets.
Screening Programs Require Physician Follow-Up
The relevant clinical point for patients: screening programs have defined age and interval criteria, and test results — a positive FIT, a suspicious mammography finding, or an abnormal cervical screening result — always require follow-up diagnostic investigation with a physician, whatever the pace of the public rollout.
The next dated milestones on record: seven of eight regional pathology hubs operating by December this year, molecular cervical screening reaching all 27 federative units by the end of 2026, the first 400,000 FIT tests by end-2026 or early 2027, and the new mammography price taking effect in 2027.
References
- Futuro da Saúde — interview with Specialized Health Care Secretary Mozart Sales, Esfera Brasil event, Wednesday, 18
- Instituto Nacional de Câncer (Inca) — cancer incidence estimates for Brazil, 2026–2028
- Ministry of Health (Brazil), Specialized Health Care Secretariat — announced priorities for the next government mandate
Worth a look
- Myo-Inositol for PCOS: Does It Improve Pregnancy or Live Birth Rates?
- New Mexico Reports 233 Shigellosis Cases Amid Bernalillo County Outbreak
- Sylvie Meis Reflects on Breast Cancer Fears at Golden Bild der Frau Gala (world-today-journal.com)
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)